The news: Regeneron struck a deal with the Trump administration to cut drug prices and increase US manufacturing in exchange for a three-year tariff exemption.

• Regeneron will offer its newly approved gene therapy, Otarmeni, for an ultra-rare genetic hearing loss at no cost in the US.
• Its cholesterol-lowering drug Praulent will sell for $225, a 58% discount, on the TrumpRx portal website, and the company said future drugs will launch at most-favored nation prices.
• Regeneron will lower its Medicaid drug prices in line with other developed countries.
• It also plans to invest $27 billion in R&D and manufacturing in the US by 2029.

Why it matters: Regeneron is the 17th pharma company to strike a deal with the administration—and the last in President Trump’s initial round of dealmaking. More deals are likely as the White House negotiates with other drugmakers.

Each of the 17 drugmakers agreed to cut prices on a handful of brand-name drugs and sell them directly on TrumpRx under three-year deals that increase US manufacturing and delay tariffs. Earlier this month, the president said he would impose tariffs up to 100% on brand-name drugs from manufacturers without deals. He set a deadline of 120 days for larger drugmakers and 180 days for smaller ones.

Implications for pharma companies: While the administration has succeeded in pushing drugmakers to cut prices, the limited number of drugs and short deal duration reduce the overall effect.

The bigger risk is that these deals set a precedent for government-backed pricing benchmarks and increase pressure to codify most-favored-nation pricing into law. That could compress pharma margins, reshape how drugmakers price and launch new therapies in the US, and make them more selective in allocating R&D for new drugs. This wave of deals may be done, but the broader fight over drug pricing—and the government’s role in setting it—will continue.

This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.